Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jul 21;5(2):e000897.
doi: 10.1136/rmdopen-2019-000897. eCollection 2019.

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis

Alexandre Virone  1 , Jean-Philippe Bastard  2   3 , Soraya Fellahi  2   3 , Jacqueline Capeau  3 , Stéphanie Rouanet  4 , Jean Sibilia  5 , Philippe Ravaud  6 , Francis Berenbaum  1   3 , Jacques-Eric Gottenberg  5 , Jérémie Sellam  1   3
Affiliations
Clinical Trial

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis

Alexandre Virone et al. RMD Open. .

Abstract

Background: To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA).

Methods: We evaluated the serum levels of lipoprotein-associated apoproteins ApoA1 and ApoB100 and lipoprotein(a) (Lp(a)) and the leptin/adiponectin ratio (LAR) as an insulin resistance proxy in patients with RA from the Rotation Or Change (ROC) trial treated with either a second-line TNFi or another biologic (tocilizumab (TCZ), rituximab or abatacept) at baseline and week 24. We compared the changes in biomarker levels in each group and according to the EULAR response.

Results: Of the 300 patients enrolled in the ROC trial, 203 were included in the study, including 96 in the second-line TNFi group and 107 in the other biological group. The measured biomarkers did not deteriorate between baseline and week 24 regardless of the group. A greater improvement in the LAR was noted in the other biological group (median (IQR) -0.12 ng/µg (-0.58 to 0.31) vs 0.04 (-0.19 to 0.43), p=0.033), and a greater improvement in the Lp(a) level was observed following treatment with TCZ than with a TNFi (-0.05 g/L (-0.11 to -0.01) vs -0.01 g/L (-0.02 to 0.01), p<0.001). When considering the patients' responses to treatment, improved biomarkers were mainly observed in the EULAR responders in each treatment group.

Conclusions: TNFis and non-TNFis were neutral on improved CVD risk-associated biomarkers in patients with RA insufficiently controlled by TNFis. TCZ could be associated with a better improvement concerning Lp(a) and LAR than TNFis. This improvement could be related to a good therapeutic response, thereby supporting the need of good control of RA.

Trial registration number: ClinicalTrials.gov Identifier NCT01000441, registered on 22 October 2009.

Keywords: adipokine; apolipoprotein; biological agents; cardiovascular risk; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JSe: consulting fees and symposia: BMS, Janssen, Menarini, MSD, Pfizer, Roche France, Fresenius Kabi, Lilly, Sandoz and Abbvie; research grants: Roche France and Pfizer. JC: fees for academic conferences by Janssen, MSD, ViiV Healthcare, Gilead, Chugai and Novartis. JSi: fees from Abbvie, Bristol-Myers Squibb, Merck, Sharp, Dohme, UCB, Pfizer, Roche, Novartis, GlaxoSmithKline, Actelion, Amgen and Hospira. FB: current or past board member of Pfizer, Abbvie, Merck Serono, Servier, Expanscience, Sanofi, UCB, Novartis, Biogaran, Biogen and Proxymagen; consultant for Janssen and Flexion; received grants from Servier and TRB Chemedica; and is on speaker’s bureau for Servier and Abbvie. J-EG: consulting fees and research grants: Abbvie, BMS, MSD, UCB, Roche and Pfizer.

References

    1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. . Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524–9. 10.1136/annrheumdis-2011-200726 - DOI - PubMed
    1. Ogdie A, Yu Y, Haynes K, et al. . Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74:326–32. 10.1136/annrheumdis-2014-205675 - DOI - PMC - PubMed
    1. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis & Rheumatism 2002;46:862–73. 10.1002/art.10089 - DOI - PubMed
    1. Sattar N, McCarey DW, Capell H, et al. . Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis. Circulation 2003;108:2957–63. 10.1161/01.CIR.0000099844.31524.05 - DOI - PubMed
    1. Conroy RM, Pyörälä K, Fitzgerald AP, et al. . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the score project. Eur Heart J 2003;24:987–1003. 10.1016/S0195-668X(03)00114-3 - DOI - PubMed

Publication types

MeSH terms

Associated data